The past, the present and the future of experimental research on myocardial ischemia and protection.
Journal Title: Pharmacological Reports - Year 2009, Vol 61, Issue 1
Abstract
At present, cardiovascular diseases represent the most important health risks because they are responsible for more than 50% of total mortality. Among them, ischemic heart disease is the leading cause of morbidity and mortality, and according to the World Health Organization, will be the major global cause of death by the year 2020. Major progress in the prognosis, diagnosis and therapy of ischemic heart disease would be impossible without notable achievements of the 20th century that have been critical for further development of cardiology.We are now living in the era of molecular medicine, and the influence of basic research on clinical practice has never been more pronounced. This, however, necessitates a new strategy; future cardiovascular research should include the following general guidelines: 1) to evaluate the role and proportion of already described molecular pathways; descriptive approaches will gradually disappear; 2) to distinguish between acute, chronic and pleiotropic effects of different drugs under in vitro and in vivo conditions, with respect to possible clinical use; 3) to use clinically relevant genetic models; 4) to study possible alterations in intracellular signaling in order to find the decisive steps responsible for abnormal control of cell growth, contractile function, lipid metabolism, cardiac ischemic tolerance, etc.; 5) to study the molecular mechanisms of cardiovascular diseases not only in healthy individuals, but also under different pathological conditions. Such an approach must include developmental and gender differences, which are particularly important for the field of ischemic heart disease; therefore, experimental cardiovascular research can no longer be restricted to males of uncertain age. It is hoped that patients in future decades will profit from the progress of basic cardiovascular research.
Authors and Affiliations
Bohuslav Ostadal
Keywords
Related Articles
- EP ID EP84369
- DOI -
- Views 114
- Downloads 0
Microparticles are vectors of paradoxical information in vascular cells including the endothelium: role in health and diseases.
Both inflammation and thrombosis can be orchestrated by the interactions between circulating cells, such as leukocytes and platelets, with vascular, endothelial and smooth muscle cells, which, during activation or apopto...
Frequency-dependent inhibition of antidromic hippocampal compound action potentials by anti-convulsants.
Using rat hippocampal slices, extracellularly recorded antidromic compound action potentials (cAP) were produced in CA1 pyramidal cell populations by electrical stimulation of the alveus at 0.5 Hz. These responses were a...
Systemic perfluorohexane attenuates lung injury induced by lipopolysaccharide in rats: the role of heme oxygenase-1.
Clinical trials with partial liquid ventilation demonstrate improvement in oxygenation, as well as some adverse side effects linked to the application of liquid perfluorocarbons (PFCs) during liquid ventilation. Thus, we...
Inhibition of NAD(P)H oxidase attenuates aggregation of platelets from high-risk cardiac patients with aspirin resistance.
Up to one-third of serious vascular events in high-risk patients is attributable to a failure of aspirin (ASA) to suppress platelet aggregation. We hypothesized that inhibition of NAD(P)H oxidase may inhibit aggregation...
In vitro effects of serotonin and noradrenaline reuptake inhibitors on human platelet adhesion and coagulation.
Background: Although several studies show that there is an increased risk of bleeding events during antidepressant treatment with selective serotonin reuptake inhibitors (SSRIs), few studies show direct effects in vitro...